NCT02905006

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 250 (actual)
• Sponsor: UCB Biopharma S.P.R.L. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of Bimekizumab compared with placebo in adult subjects with moderate to severe chronic plaque psoriasis in order to guide the selection of doses and clinical indices in the Phase 3 development program.

Conditions

• Chronic Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Bimekizumab	Subjects will be randomized to receive a combination of injections of Bimekizumab.
OTHER	Placebo	Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.

Timeline

• Start date: 2016-08-01
• Primary completion: 2017-06-01
• Completion: 2017-07-01
• First posted: 2016-09-19
• Last updated: 2022-07-21
• Results posted: 2020-11-19

Locations

41 sites across 6 countries: United States, Canada, Czechia, Hungary, Japan, Poland